The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years ...

Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as Vykat XR – to treat extreme hunger in patients with Prader-Willi syndrome.

Soleno Therapeutics won approval for a drug that treats excessive hunger associated with a rare disease, and the biotech stock rocketed.

Soleno Therapeutics today announced that the US FDA has approved VYKAT XR (diazoxide choline) extended-release tablets, for ...

Soleno Therapeutics (SLNO) “announced that the FDA has approved VYKAT XR, diazoxide choline, extended-release tablets, previously referred to ...

Federal regulators are clearing a first-of-its-kind treatment for symptoms of a rare neurodevelopmental disorder that is characterized by insatiable hunger.

Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares are trading higher Thursday after the company announced it secured FDA approval for its first commercial drug, Vykat XR (diazoxide choline) ...

Soleno Therapeutics (SLNO) stock jumped over 32% in yesterday’s after-hours trading. The surge came after the company announced that the U.S.

Shares of the Redwood City-based Soleno Therapeutics climbed 38% — the biggest one-day gain since September 2023 — to their ...

The U.S. Food and Drug Administration on Wednesday approved Soleno Therapeutics' drug to treat a rare genetic disorder, making it the first treatment available for patients who experience feelings of ...

Credit: Solano Therapeutics. Vykat XR contains an extended-release formulation of diazoxide choline, the crystalline salt of diazoxide. Vykat XR is expected to be available in April 2025.

Vykat XR is specifically indicated to address hyperphagia, or the abnormally strong sensation of hunger, which often leads to excessive eating. Its approval covers both adult and pediatric patients ...